Spago Nanomedical
0.334 SEK -14.8%Be the first to follow this company
Spago Nanomedical conducts research and development in cancer diagnostics. The company conducts various development projects based on its proprietary nanomaterials whose potential is found in making tumours visible, and enabling internal radiation therapy of cancer. The company was founded in 2007 and is based in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SPAGO
Daily low / high price
0.322 / 0.388
SEK
Market cap
116.3M SEK
Turnover
165.51K SEK
Volume
480K
Financial calendar
Interim report
21.08.2024
Interim report
06.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Peter Lindell | 40.5 % | 40.5 % |
Mikael Lönn | 8.5 % | 8.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Spago Nanomedical announces outcome of the exercise of warrants series TO12
Spago Nanomedical receives declarations of intent from the largest owner, board and management team regarding the exercise of TO12
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools